CPT-SS-DEX-PTD NPs

CPT-SS-DEX-PTD NPs are investigational pH- and glutathione-responsive dextran-based polymeric prodrug nanoassemblies that covalently incorporate the topoisomerase I inhibitor camptothecin and the immunomodulatory dipeptide pidotimod. Camptothecin is linked to dextran through a disulfide-containing linker intended to enable glutathione-responsive intracellular release, while pidotimod is ester-linked for release in the weakly acidic tumor microenvironment. The approximately 180 nm nanoparticles produced antitumor activity with reduced camptothecin-associated toxicity in a murine 4T1 breast cancer model, supporting a preclinical chemo-immunotherapy strategy. ([arxivlens.com](https://arxivlens.com/paperview/details/dextran-based-prodrug-nanoassemblies-responsively-releasing-pidotimod-and-camptothecin-for-anti-breast-cancer.-4761-580334))

Other names

CPT-SS-DEX-PTD NPsCPT-SS-Dex-PTDCPT-SS-Dex-PTD nano-micelles